<?xml version='1.0' encoding='utf-8'?>
<document id="28912253"><sentence text="Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions."><entity charOffset="59-71" id="DDI-PubMed.28912253.s1.e0" text="Panobinostat" /></sentence><sentence text="Panobinostat (Farydak) is an orally active hydroxamic acid-derived histone deacetylase inhibitor used for the treatment of relapsed or refractory multiple myeloma"><entity charOffset="0-12" id="DDI-PubMed.28912253.s2.e0" text="Panobinostat" /><entity charOffset="43-58" id="DDI-PubMed.28912253.s2.e1" text="hydroxamic acid" /><pair ddi="false" e1="DDI-PubMed.28912253.s2.e0" e2="DDI-PubMed.28912253.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28912253.s2.e0" e2="DDI-PubMed.28912253.s2.e1" /></sentence><sentence text=" Based on recombinant cytochrome P450 (P450) kinetic analyses in vitro, panobinostat oxidative metabolism in human liver microsomes was mediated primarily by CYP3A4 with lower contributions by CYP2D6 and CYP2C19" /><sentence text=" Panobinostat was also an in vitro reversible and time-dependent inhibitor of CYP3A4/5 and a reversible inhibitor of CYP2D6 and CYP2C19"><entity charOffset="1-13" id="DDI-PubMed.28912253.s4.e0" text="Panobinostat" /></sentence><sentence text=" Based on a previous clinical drug-drug interaction study with ketoconazole (KTZ), the contribution of CYP3A4 in vivo was estimated to be âˆ¼40%"><entity charOffset="63-75" id="DDI-PubMed.28912253.s5.e0" text="ketoconazole" /><entity charOffset="77-80" id="DDI-PubMed.28912253.s5.e1" text="KTZ" /><pair ddi="false" e1="DDI-PubMed.28912253.s5.e0" e2="DDI-PubMed.28912253.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28912253.s5.e0" e2="DDI-PubMed.28912253.s5.e1" /></sentence><sentence text=" Using clinical pharmacokinetic (PK) data from several trials, including the KTZ drug-drug interaction (DDI) study, a physiologically based pharmacokinetic (PBPK) model was built to predict panobinostat PK after single and multiple doses (within 2-fold of observed values for most trials) and the clinical DDI with KTZ (predicted and observed area under the curve ratios of 1"><entity charOffset="77-79" id="DDI-PubMed.28912253.s6.e0" text="KTZ" /><entity charOffset="315-317" id="DDI-PubMed.28912253.s6.e1" text="KTZ" /><pair ddi="false" e1="DDI-PubMed.28912253.s6.e0" e2="DDI-PubMed.28912253.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28912253.s6.e0" e2="DDI-PubMed.28912253.s6.e1" /></sentence><sentence text="8)" /><sentence text=" The model was then applied to predict the drug interaction with the strong CYP3A4 inducer rifampin (RIF) and the sensitive CYP3A4 substrate midazolam (MDZ) in lieu of clinical trials" /><sentence text=" Panobinostat exposure was predicted to decrease in the presence of RIF (65%) and inconsequentially increase MDZ exposure (4%)"><entity charOffset="1-13" id="DDI-PubMed.28912253.s9.e0" text="Panobinostat" /></sentence><sentence text=" Additionally, PBPK modeling was used to examine the effects of stomach pH on the absorption of panobinostat in humans and determined that absorption of panobinostat is not expected to be affected by increases in stomach pH" /><sentence text=" The results from these studies were incorporated into the Food and Drug Administration-approved product label, providing guidance for panobinostat dosing recommendations when it is combined with other drugs" /><sentence text="" /></document>